4503 — Astellas Pharma Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapSuper Stock

Annual cashflow statement for Astellas Pharma, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	156,886	132,361	24,969	31,237	376,587
Depreciation
Non-Cash Items	73,650	85,167	79,480	197,367	60,233
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-52,777	4,501	-89,813	-233,225	-71,226
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	257,443	327,767	172,476	194,511	560,188
Capital Expenditures	-76,448	-88,541	-82,497	-57,330	-84,645
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	14,035	4,041	-763,305	-32,089	17,923
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-62,413	-84,500	-845,802	-89,419	-66,722
Financing Cash Flow Items	-2,530	-3,217	-16,539	-23,813	14,944
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-216,298	-195,623	614,060	-261,367	-404,779
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-10,143	60,854	-41,153	-147,315	93,234